|
Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013
|
23 January 2013 |
|
Novartis makes progress in the fight to eliminate leprosy worldwide
|
21 January 2013 |
|
Phase III data show significant benefit of Novartis drug Afinitor® in patients with non-cancerous tumors associated with TSC
|
13 January 2013 |
|
Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease
|
16 December 2012 |
|
Novartis highlights key data in patients with hematologic diseases and breast cancer
|
28 November 2012 |
|
Novartis receives FDA approval for Flucelvax®
|
21 November 2012 |
|
Novartis future growth prospects secured by industry-leading pipeline
|
08 November 2012 |
|
Novartis to start construction of new biotechnology facility in Singapore
|
31 October 2012 |
|
Recently launched products support Novartis sales in third quarter
|
25 October 2012 |
|
New data for Novartis drug Lucentis® confirms long-term efficacy and safety profile and benefits of individualized treatment
|
05 September 2012 |